EN DE
Watch Dentsply Sirona Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Dentsply Sirona Inc (XRAY) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Dentsply Sirona Inc stock $2.02, price $9.46, that is 78.6% below the price, quality 48 out of 100. Rating: strongly overvalued. Calculated from audited financials with 5 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

DS Dentsply Sirona Inc logo Some data Nov 6, 2026

Dentsply Sirona Inc

XRAY · US
Very expensive, weak quality

Our calculation puts a fair price 79% below what the stock costs today.

Generates free cash flow
3.4% dividend yield · Cash covered
Quality 48/100
Insiders bought $617,315 (6M)
Some data
Fair value $2.02 · Strongly overvalued (−78.6%)
Weak Growth (revenue 3y −2.1 %/yr in USD)
Loss-making · -15.0% net margin (TTM) · excl. goodwill write-downs -3.6%
High debt
Trails peers (5/13)
Narrow moat 23/100
Watch Dentsply Sirona Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$56.13 $8.42 Fair Value $2.02 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $8.42 – $56.13 · fair‑value band $1.23 – $6.14 · the $9.46 price screens above the $2.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Dentsply Sirona in your weekly email

Every Wednesday you see whether Dentsply Sirona is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide.

Show moreShow less

It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare.

The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering.

The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedures; restorative products; curing light and dental diagnostic systems; ultrasonic scalers and polishers; and dental anesthetics, prophylaxis paste, dental sealants, and impression materials.

The Orthodontic and Implant Solutions segment offers SureSmile, a clear aligner solution that includes whitening kits and retainers; VPro, a high frequency vibration technology device; SureSmile Simulator; DS Core platform, which creates 3D visualization of patient outcomes; dental implant products; digital dentures; crown and bridge porcelain products; bone regenerative and restorative solutions; treatment planning software; educational programs; custom abutments; tapered immediate load screws; regenerative bone growth factor; artificial teeth; and precious metal dental alloys.

The Wellspect Healthcare segment offers medical devices, including catheters for urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation.

The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina.

Stock analysis

Dentsply Sirona Inc (XRAY) currently trades at $9.46, while our model-based Fair Value estimate is $2.02, 79% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $3.62 per share, and 0 of the 5 models we run sit above the $9.46 price.

Bear case: the DCF Models group reads lowest at $2.02, and 5 of the 5 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $1.23 (bear) to $6.14 (bull), the price of $9.46 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Dentsply Sirona Inc reported revenue of $3.7B in FY2025 versus $4.2B in FY2021, a compound −3.4%/yr. Reported net income was −$598M in FY2025.

Key figures

Market cap $1.9B Small · P/S ratio 0.55 · EPS (TTM) $−2.73 · Dividend yield 3.4% · Net margin −15.0% · Return on equity −33.0% · Return on assets (EBIT) −3.5% (5-year average) · Operating margin 9.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).

What moves the price

The share trades about 36% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −79%, XRAY screens richer than that median.

Fair Value models

Bear $1.23 Fair Value $2.02 Bull $6.14
Price $9.46 · Downside -78.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $1.23 $6.77 $15.15 72
Growth DCF $1.33 $6.14 $12.91 71
5Y Revenue Exit n/a $1.00 >$4.00 69
All 5 models by family
DCF Models
FCF DCF $1.23 $6.77 $15.15 72
5Y Revenue Exit n/a $1.00 >$4.00 69
10Y Revenue Exit n/a $2.02 $6.14 64
Growth DCF
Growth DCF $1.33 $6.14 $12.91 71
Rev-Margin DCF n/a $1.09 >$4.36 69

Open the full fair value analysis →

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 22
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 16
Debt, balance sheet and risk of trouble
Investment 97
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 12
Distance to the 52-week high, does not count
New shares 87
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 6 officers or directors bought shares worth $617,315, most recently on Jun 15, 2026. Buying cluster

  • BuyClyde HoseinDirector6,500 shares at $9.99$64,935Jun 15, 2026
  • BuyBrian T GladdenDirector9,985 shares at $10.02$100,050Jun 15, 2026
  • BuyJonathan Jay MazelskyDirector10,000 shares at $10.14$101,400Jun 12, 2026
  • BuyBrian P McKeonDirector10,000 shares at $10.12$101,200Jun 12, 2026
  • BuyMichael J BarberDirector15,175 shares at $9.89$150,081Jun 11, 2026
  • BuyBetsy D HoldenDirector10,086 shares at $9.88$99,650Jun 11, 2026
  • BuyJames D ForbesDirector2× since Mar 3, 2026: 10,000 shares, avg. $12.98$129,750Mar 9, 2026
  • BuyGregory T LucierDirector2× since Mar 2, 2026: 65,000 shares, avg. $13.76$894,312Mar 9, 2026
  • SaleGregory T LucierDirector82,200 shares at $11.14$915,708Dec 8, 2025
  • BuyLeslie F VaronDirector9,337 shares at $10.71$99,999Nov 24, 2025

Plus 15 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−3.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Start year 2020 (pandemic). Over 10 years: +3.2% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
8.8% (2019) → −23.2% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+0.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +17.6% a year for the price and −1.9% for the forecasts.
Forecast 2026 (sales)−3.0%
Forecast 2027 (sales)+1.2%
Projected 2028 (sales)+1.3%
Projected 2029 (sales)+1.4%
Projected 2030 (sales)+1.5%

XRAY screens overvalued: fair value 79% below the price. Compare with Intuitive Surgical, Inc →

Compare Dentsply Sirona Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 48 · Bottom 25%
Fair Value upside −78.6% · Bottom 25%
Profitability
Return on assets −11.0% · Bottom 25%
Net margin (12 months) −15.0% · Bottom 25%
Operating margin (12 months) 9.2% · Below median
Growth and dividend
Revenue growth (quarter YoY) −4.1% · Bottom 25%
Dividend yield (12 months) 3.4% · Top 25%
Balance sheet
Debt / equity 1.50× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 1.42× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 0.52× · Cheapest 25%
Price / free cash flow (fiscal year) 18.2× · Cheaper than median
EV/EBITDA 6.8× · Cheapest 25%
PEG 0.72× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 25
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 31
HEALTH (low debt)25 · sector 96
DIVIDEND (yield)68 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.38 $131.06 +45% vs XRAY
EssilorLuxottica Société anonyme EL €193.80 €196.22 +1% vs XRAY
Intuitive Surgical, Inc ISRG $452.80 $353.90 −22% vs XRAY
Medline Inc MDLN $39.64 $28.59 −28% vs XRAY
Alcon Inc ALC CHF 61.30 CHF 33.91 −45% vs XRAY
Straumann Holding STMN CHF 104.50 CHF 45.50 −56% vs XRAY
Becton, Dickinson and Company BDX $211.88 $82.34 −61% vs XRAY
West Pharmaceutical Services, Inc WST $399.81 $139.22 −65% vs XRAY
Sartorius Stedim Biotech S.A DIM €225.80 €54.82 −76% vs XRAY
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs XRAY

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Dentsply Sirona Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Dentsply Sirona Inc Fair Value". https://www.fairvalue-calculator.com/stock/XRAY

Frequently asked questions

Is Dentsply Sirona Inc (XRAY) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $2.02 versus a price of $9.46, about 79% lower (overvalued).
What is the fair value of XRAY?
Our model-based fair value for Dentsply Sirona Inc is $2.02 (as of Nov 6, 2026), built from audited fundamentals. The current price: $9.46.
What is the quality score of XRAY?
Dentsply Sirona Inc has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dentsply Sirona Inc (XRAY)?
Our model-based price target is the fair value of $2.02 (as of Nov 6, 2026) from 5 valuation models. Cautious scenario $1.23, optimistic scenario $6.14. It is a calculation from audited fundamentals, not an analyst target.
What is the Dentsply Sirona Inc stock forecast for 2026?
Our models put fair value at $2.02, about 79% lower versus a price of $9.46 (overvalued). Cautious scenario $1.23, optimistic scenario $6.14. The calculation is refreshed regularly with new filings.
What is the revenue of Dentsply Sirona Inc (XRAY)?
Dentsply Sirona Inc reported trailing-twelve-month revenue of about $3.6B (latest available figure, as of Nov 6, 2026).
Does Dentsply Sirona Inc pay a dividend?
Dentsply Sirona Inc currently shows a dividend yield of 3.38% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Dentsply Sirona Inc (XRAY) and when is the ex-dividend date?
Dentsply Sirona Inc pays a dividend of $0.32 per share a year, a dividend yield of 3.4%. The last ex-dividend date was Dec 26, 2025. A dividend has been paid every year since at least 1994. Free cash flow covers the dividend 1.63 times. Our assessment: Cash covered. The dividend is fully funded by free cash flow. The payout ratio on earnings is not available for this company.
What growth is priced into Dentsply Sirona Inc (XRAY)?
For today's price to be fair in a discounted-cash-flow model, Dentsply Sirona Inc would have to grow free cash flow by +20.4 % per year for five years (discount rate 9.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.0 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of XRAY use?
Our models discount Dentsply Sirona Inc at 9.4 %: a base by market capitalisation (mid), damped by beta 0.86, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Dentsply Sirona Inc that is +20.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.4 %) and the same formula as our fair value.
How much growth has Dentsply Sirona Inc (XRAY) delivered so far?
Over the past 5 years revenue at Dentsply Sirona Inc grew +2.0 % a year. The price currently implies free-cash-flow growth of +20.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Dentsply Sirona Inc (XRAY) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Dentsply Sirona Inc (+20.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Dentsply Sirona Inc (XRAY)?
The free-cash-flow yield on the price is 5.48 %: that much free cash flow Dentsply Sirona Inc produces per unit of market value. When it exceeds the discount rate of our models (9.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Dentsply Sirona Inc (XRAY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dentsply Sirona Inc it is $2.02 per share (as of Nov 6, 2026), against a price of $9.46. It is the blended result of 5 valuation models in 2 families (DCF Models, Growth DCF).
Is Dentsply Sirona Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, XRAY trades above its calculated fair value: price $9.46, fair value $2.02, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of XRAY?
No. The price is what the market pays today ($9.46); the fair value is what the company's own numbers justify ($2.02). For Dentsply Sirona Inc the two are $7.44 per share apart. That gap is exactly why we show both numbers side by side.
How much is Dentsply Sirona Inc worth?
The market values Dentsply Sirona Inc at about $1.9B (market capitalisation, as of Nov 6, 2026). Per share that is $9.46; our models calculate a fair value of $2.02 per share.
What do the bullish and bearish scenarios say about XRAY?
Our models span a range for Dentsply Sirona Inc: cautious scenario $1.23, base $2.02, optimistic $6.14 per share (as of Nov 6, 2026, price $9.46). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of XRAY?
The PEG ratio of Dentsply Sirona Inc is 0.72 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Dentsply Sirona Inc (XRAY)?
Balance-sheet figures for Dentsply Sirona Inc (as of Nov 6, 2026): return on equity −33.0%, debt of 1.50 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is XRAY from its 52-week high?
Dentsply Sirona Inc trades at $9.46, about 36% below its 52-week high of $14.68 and 12% above the low of $8.42 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $2.02 is for.
Which stocks are comparable to Dentsply Sirona Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dentsply Sirona Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $9.46, calculated fair value $2.02 (−79%), Quality Score 48/100, from 5 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of XRAY calculated?
We run Dentsply Sirona Inc through 5 models from 2 families: DCF Models, Growth DCF. Every model gets the same audited fundamentals; the fair value of $2.02 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Dentsply Sirona Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dentsply Sirona Inc (XRAY)?
The closing price on Nov 6, 2026 was $9.46. Our model-based fair value is $2.02, about 79% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dentsply Sirona Inc right now?
The price sits above even our optimistic bull case ($6.14). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($1.23 to $6.14). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Key figures of Dentsply Sirona Inc

How large is the market capitalisation of Dentsply Sirona Inc (XRAY)?
The market capitalisation of Dentsply Sirona Inc is $1.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dentsply Sirona Inc (XRAY)?
The price-to-sales ratio of Dentsply Sirona Inc is 0.55 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Dentsply Sirona Inc (XRAY)?
Earnings per share at Dentsply Sirona Inc are $−2.73. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Dentsply Sirona Inc (XRAY)?
The dividend yield of Dentsply Sirona Inc is 3.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Dentsply Sirona Inc (XRAY)?
The net margin of Dentsply Sirona Inc is −15.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Dentsply Sirona Inc (XRAY)?
The return on equity (ROE) of Dentsply Sirona Inc is −33.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dentsply Sirona Inc (XRAY)?
On an EBIT basis the return on assets of Dentsply Sirona Inc is −3.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dentsply Sirona Inc (XRAY)?
The operating margin of Dentsply Sirona Inc is 9.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dentsply Sirona Inc (XRAY)?
Revenue at Dentsply Sirona Inc is growing −4.1% versus a year earlier (3y avg −2.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Dentsply Sirona Inc (XRAY)?
Earnings per share at Dentsply Sirona Inc are growing +15.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Dentsply Sirona Inc (XRAY) carry?
The net debt of Dentsply Sirona Inc is $2.1B (fiscal year 2025, ≈ 20.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Dentsply Sirona Inc in the live analysis

One click puts Dentsply Sirona Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.